CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymph...
Phase 3
Boston, Massachusetts, United States and 8 other locations
This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia...
Phase 1
Boston, Massachusetts, United States and 3 other locations
in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...
Phase 1, Phase 2
Boston, Massachusetts, United States and 55 other locations
in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia...
Phase 2
Boston, Massachusetts, United States and 8 other locations
in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...
Phase 1
Boston, Massachusetts, United States and 7 other locations
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Boston, Massachusetts, United States and 56 other locations
Adult T-cell leukemia/lymphoma (ATLL) is a rare form of cancer found mostly among people from the Caribbean islands, Western Africa, Brazil,...
Phase 2
Boston, Massachusetts, United States and 3 other locations
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)...
Phase 1, Phase 2
Boston, Massachusetts, United States and 7 other locations
therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia...
Phase 2
Boston, Massachusetts, United States and 3 other locations
a drug called ACY-1215 in combination with ibrutinib or idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia...
Phase 1
Boston, Massachusetts, United States
Clinical trials
Research sites
Resources
Legal